In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Neurosense Therapeutics Ltd. (NRSN – Research Report), with a price target of $7.00. The company’s shares opened today at $1.65.
According to TipRanks, Rahman is an analyst with an average return of -35.8% and a 20.24% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Agile Therapeutics, 9 Meters Biopharma, and Neurosense Therapeutics Ltd..
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurosense Therapeutics Ltd. with a $7.00 average price target.
See the top stocks recommended by analysts >>
Based on Neurosense Therapeutics Ltd.’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.48 million. In comparison, last year the company had a GAAP net loss of $2.12 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer’s disease and Parkinson’s disease, among others. Its lead product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Read More on NRSN:
